Nurix is a Brisbane, California biopharmaceutical company developing cancer and inflammation drugs that remove disease-causing proteins. It last closed at $12.85 on Nov 20, down 5.51% on the day. The next earnings report for NRIX is expected around Wed, Jan 27, 2027, after the close. For the quarter ended Aug 2026, NRIX reported EPS of $4.73 on revenue of $673.1M, with revenue up 8426.3% from a year ago. Over its last 8 reports the stock moved an average of 4.3% the session after earnings. Over the last 12 months NRIX insiders bought $0 of stock on the open market and sold $5.8M, according to SEC Form 4 filings.
AI Auto Pilots
Is NRIX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NRIX.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on NRIXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
NRIX · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 48% below its 20 day and 72% below its 50 day average. It is 56% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 21), oversold. The nearest support is the 52 week low at $12.82, and the nearest resistance the Pivot at $13.12.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 10.3%/day
Key levels
$28.2352 week high+119.7%
$23.56100 day average+83.3%
$22.0750 day average+71.8%
$20.06200 day average+56.1%
$19.0020 day average+47.9%
$16.76Swing high (Nov 10)+30.4%
$13.41Pivot R1+4.4%
$13.12Pivot+2.1%
$12.85Last close
$12.8252 week low−0.2%
$12.56Pivot S1−2.3%
Indicators
RSI (14)
21.23
Oversold below 30
Oversold
MACD
-2.85
Below its signal line
Bearish
Stochastic
1.3
Near the bottom of its range
Oversold
ADX (14)
41.6
Strong downtrend
Williams %R
-99.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-77.9
Oversold below −100, overbought above 100
Neutral
Rate of change
−16.0%
Change over 10 sessions
Bearish
ATR (14)
$1.32
Typical daily range, 10.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityNormal, 22.7%/day
Key levels
$28.2352 week high+119.7%
$23.56100 day average+83.3%
$22.0750 day average+71.8%
$20.06200 day average+56.1%
$19.0020 day average+47.9%
$16.76Swing high (Nov 10)+30.4%
$13.41Pivot R1+4.4%
$13.12Pivot+2.1%
$12.85Last close
$12.8252 week low−0.2%
$12.56Pivot S1−2.3%
Indicators
RSI (14)
32.14
Weak, oversold below 30
Neutral
MACD
-0.52
Below its signal line
Bearish
Stochastic
3.1
Near the bottom of its range
Oversold
ADX (14)
24.2
Weak trend
Williams %R
-99.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-269.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−48.8%
Change over 10 sessions
Bearish
ATR (14)
$2.92
Typical daily range, 22.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NRIX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how NRIX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow NRIX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for NRIXHow many large options trades hit NRIX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in NRIX in the last 90 days.
From SEC Form 4 filings by NRIX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NRIX is in one of them and how their past NRIX trades turned out.
Nurix is a clinical stage biopharmaceutical company based in Brisbane, California. It develops medicines based on targeted protein degradation, a approach that removes disease-causing proteins, with a focus on cancer and inflammatory conditions. Its lead candidate, bexobrutideg, is being studied in patients with relapsed or refractory chronic lymphocytic leukemia. The company also works with large drug makers, including Gilead, Sanofi and Pfizer, on collaborations that use its platform, which combines DNA encoded libraries with artificial intelligence, to find new drug candidates.